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Abstract
Background—The association between abacavir (ABC) and cardiovascular disease (CVD) risk 
in HIV-infected individuals is unclear. Putative mechanisms for an effect of ABC on CVD risk 
including endothelial dysfunction have been proposed; however, a biological mechanism has not 
been established.
Methods—This was a cross-sectional study of HIV-infected subjects with HIV RNA levels <400 
copies/ml, who were randomly assigned to ABC or tenofovir (TDF) as initial therapy during a 
prior clinical trial. A small cohort of subjects on zidovudine (AZT; not randomly assigned) were 
studied to explore long-term exposure to this agent. All underwent brachial artery ultrasound for 
flow-mediated dilation (FMD), and D-dimer, high-sensitivity C-reactive protein (hsCRP), 
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interleukin-6 (IL-6) and fasting lipids were measured. Between-arm differences were evaluated by 
multivariable linear or logistic regression modelling.
Results—There were 148 subjects (46 on ABC, 72 on TDF and 30 on AZT). Demographic 
characteristics were balanced across the groups except, as expected, AZT-treated participants were 
older, had higher CD4+ T-cell counts, and longer antiretroviral therapy duration. After adjusting 
for age, brachial artery diameter, and treatment duration, FMD was similar in those on ABC 
(3.9%) and TDF (5.4%; P=0.181). FMD was higher in those on AZT (6.1%; P<0.005). Levels of 
IL-6, hsCRP and detectable D-dimer were similar between groups.
Conclusions—Among individuals assigned to ABC or TDF in randomized clinical trials there 
were no significant differences in FMD or markers of inflammation and coagulation. Whether 
ABC contributes to risk of CVD remains unclear, but our results suggest that endothelial 
dysfunction, heightened inflammation, and altered coagulation are unlikely to be mechanisms by 
which the drug could increase CVD risk above that seen with TDF.
Introduction
The role of abacavir in the development of cardiovascular disease (CVD) in HIV-infected 
patients is unclear. Observational cohort studies, in particular the D:A:D and French 
Hospital Database on HIV studies, have reported an association between exposure to 
abacavir and CVD risk [1–3]; however, retrospective analyses conducted by researchers in 
the Veterans Administration and the AIDS Clinical Trials Group (ACTG), as well as two 
meta-analyses of clinical trials involving abacavir found no such link [4–7].
Observational data may be subject to channelling bias, whereby the real or perceived risk of 
an adverse effect influences medication selection. In the Veterans Administration study, 
patients with renal insufficiency, a risk factor of increased CVD, were more likely to be 
prescribed abacavir than tenofovir and, after adjustment for renal disease, no association 
between abacavir and CVD was detected [4]. Similarly, in the French Hospital Database on 
HIV study, the association between abacavir and myocardial infarction was lost after 
accounting for differential rates of cocaine and intravenous drug use [3].
Compounding the uncertainty regarding the association between abacavir and CVD is the 
absence of a mechanism to explain how the drug could promote the development of CVD. 
Putative mechanisms, such as endothelial dysfunction, hypercoagulability, and direct pro-
inflammatory effects have been suggested [2,7–12]; however, studies examining an effect of 
abacavir on biomarkers for CVD and inflammation have provided inconsistent results [13–
16], and in vitro investigations of the effects of abacavir on cellular processes, such as 
platelet aggregation or stimulation of Toll-like receptor-8 signalling are of unclear 
significance [7,12].
To further examine the role of abacavir in CVD risk, we conducted a cross-sectional 
analysis of a sample of HIV-infected patients who had previously been randomized to 
abacavir or tenofovir as initial HIV therapy within the context of a clinical trial. 
Measurements of interest included endothelial function (flow-mediated vasodilation), 
markers of inflammation (interleukin-6 [IL-6], high-sensitivity C-reactive protein [hsCRP]), 
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coagulation (D-dimer) and lipids (fasting total, low-density lipoprotein [LDL] and high-
density lipoprotein [HDL] cholesterol, and triglyceride levels). Recruitment of patients 
randomly assigned to their nucleoside/nucleotide was intended to reduce channelling bias 
that could affect the outcomes of interest. A third group of patients treated long-term with 
zidovudine was also enrolled to examine markers of endovascular function, inflammation 
and coagulation in those treated with this nucleoside analogue and to explore differences 
between these and the abacavir- and tenofovir-treated patients.
Methods
Participants
Patients age ≥18 years with documented HIV infection, receiving continuous HIV therapy 
for ≥6 months prior to study entry and evaluation, having plasma HIV-1 RNA levels below 
the limits of detection of the assay in use at the clinical site at least twice during the 48 
weeks prior to and at study entry, and who were not pregnant were eligible to enrol provided 
they met the following antiretroviral treatment criteria: previously assigned randomly to 
abacavir or tenofovir as part of initial therapy for HIV infection during any clinical trial, 
remained on that nucleoside/nucleotide at the time of study entry, were not receiving both 
drugs at the same time, and were not taking zidovudine. Patients who had components of 
their initial antiretroviral regimen other than their abacavir or tenofovir changed, such as for 
intolerance or convenience, were not excluded.
In addition to the abacavir- and tenofovir-treated patients, a small cohort of patients 
receiving zidovudine as a component of initial therapy for HIV was recruited. By design, the 
zidovudine-treated participants were not required to have been assigned therapy in a clinical 
trial and were included in order to examine endothelial function, inflammation and 
coagulation markers in a cohort with long-term zidovudine exposure.
The study was conducted at eight academic clinical centres across the US. The institutional 
review boards at each participating institution approved the study. All participants provided 
written informed consent.
Evaluations
Endothelial function—Endothelial function was evaluated by flow-mediated dilation 
(FMD) of the brachial artery, a well-established measure of endothelium-dependent 
vasodilation, using procedures that have been described elsewhere [17–21]. Brachial artery 
reactivity studies were performed on the same day as phlebotomy. Subjects were required to 
be fasting and not use any tobacco-containing products for 8 h before the study. A blood 
pressure cuff was placed on the widest part of the proximal right forearm approximately 1 
cm distal to the antecubital fossa. Using a high resolution (≥7 MHz) linear array vascular 
ultrasound transducer, the brachial artery was located above the elbow and scanned in 
longitudinal sections with the focus zone set to the depth of the far wall. Time-gain 
compensation and overall gain settings were used to optimize images of the lumen/arterial 
wall interface. The extravascular landmarks were identified and labelled to assure that the 
imaged segment of the brachial artery was reproduced within and between studies. After 
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recording baseline B-mode images of the brachial artery and spectral Doppler images of 
flow, the forearm cuff was inflated to 250 mmHg for 4.5 min to induce reactive hyperaemia. 
Immediately after deflation, spectral Doppler images were obtained to verify hyperaemia. 
FMD of the brachial artery was measured at 60 and 90 s after cuff deflation. FMD was 
calculated as the ratio of the maximum brachial artery diameter after reactive hyperaemia to 
the baseline diameter and was expressed as a percentage change. Each study was recorded 
digitally and sent to the University of Wisconsin core ultrasound laboratory (Madison, WI, 
USA). Artery diameters were measured in triplicate with a digital border tracing tool 
(Access Point Web, Freeland Systems, Westminster, CO, USA). Measurements were 
performed by a single reader blinded to subject information and treatment.
All sonographers completed training supervised by the University of Wisconsin core 
ultrasound laboratory. After on-site training, each sonographer was required to submit a 
minimum of three paired mock studies to demonstrate adherence to the study protocol and 
consistent display of high-quality images and reproducibility of landmarks. Before study 
initiation, ultrasound equipment at each laboratory was evaluated and calibrated using a 
small parts ultrasound phantom. Blinded re-reading of 25 contemporaneous scans revealed a 
strong Pearson correlation of 0.94 (P<0.001) and a small mean difference of 0.1% (sd 0.9%; 
P=0.589). The two outliers on limits of agreement analyses were due to measurements that 
differed by <1 digital pixel.
Laboratory evaluations—After FMD was performed, blood was obtained for 
measurement of hsCRP, IL-6, D-dimer and lipid panel (total, LDL and HDL cholesterol, and 
triglycerides), and HLA-B*5701 testing. All blood specimens were drawn at the local site 
and shipped to the University of North Carolina (Chapel Hill, NC, USA) for analysis. 
hsCRP was performed by turbidometric analysis using the VITROS Chemistry System 
(Ortho Clinical Diagnostics, Rochester, NY, USA) and IL-6 levels were determined with 
Quantikine Human IL-6 Immunoassay (R&D Systems, Inc., Minneapolis, MN, USA). D-
dimer levels were measured using latex agglutination. HLA-B*5701 testing (LabType SSO 
high definition HLA-B kit, One Lambda, Inc., Canoga Park, CA, USA) was conducted on 
all participants.
Statistical analyses—The primary objective was to determine whether there are 
significant differences in FMD between participants receiving abacavir compared to 
tenofovir. The secondary objective was to determine if there were significant differences in 
markers of inflammation and coagulation between participants receiving abacavir compared 
to tenofovir. Comparisons with zidovudine were considered exploratory and were performed 
to provide context to the results from the other two groups. To detect an FMD difference of 
2% (sd 4%) between abacavir and tenofovir, 70 subjects per group were required (α=0.05, 
1-β=0.80). For descriptive purposes, a target of 30 zidovudine-receiving patients was 
planned. Recruitment targets were achieved for the tenofovir and zidovudine groups. 
Enrolment of the abacavir group was halted at 65% of target sample size due to lack of 
additional available patients at the study sites. Between-group differences were evaluated by 
ANOVA and multivariable linear regression modelling; the binomial test was used for 
proportions. A series of multivariable linear regression models were created to determine if 
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drug treatment group was associated with differences in FMD, IL-6, hsCRP, D-dimer, 
cholesterol fractions and triglyceride levels after adjustment for age and antiretroviral 
therapy duration. Adjustment for baseline brachial artery diameter (as recommended by the 
American Society of Echocardiography) was also performed for analysis of FMD [22]. 
Exploratory analyses investigated the effects of parameters that differed by treatment group, 
including CD4+ T-cell count, use of protease inhibitors, and use of statins. All variables are 
described as means (sem).
Results
Participant characteristics
A total of 148 participants were recruited: 46 receiving abacavir, 72 receiving tenofovir and 
30 receiving zidovudine. The characteristics of the participants are included in Table 1. The 
majority of the participants receiving abacavir and tenofovir were previously enrolled in 
ACTG study A5202 (78% and 96%, respectively), with the remainder formerly in other 
ACTG, investigator-initiated, or industry-sponsored studies. Overall, the abacavir and 
tenofovir groups were balanced in terms of demographic characteristics; however, 
participants on abacavir had a slightly but statistically significant longer duration of 
antiretroviral therapy than those on tenofovir (4.0 versus 3.6 years; P=0.015) and were more 
likely to be receiving protease inhibitors (67% versus 48%; P=0.041). As anticipated, the 
zidovudine-receiving participants had a longer duration of HIV therapy (P<0.001 for both), 
were older (P<0.08 versus abacavir and P<0.009 versus tenofovir), and had greater statin use 
(P<0.029 for both) than those in the abacavir and tenofovir groups.
Endothelial function
FMD in the abacavir and tenofovir groups was not significantly different from each other 
(4.2% [2.83%] versus 4.8% [2.82%]; P=0.2). After adjusting for age, brachial artery 
diameter and antiretroviral therapy duration, FMD in the abacavir and tenofovir groups was 
not significantly different (3.9% [0.4%] versus 4.5% [0.3%]; P=0.181; Table 2 and Figure 
1). Age, CD4+ T-cell count, current treatment with protease inhibitors, and current statin 
treatment were not independent predictors of FMD and addition of these variables did not 
improve models of FMD (data not shown).
Inflammation, coagulation and lipids
There were no significant differences between abacavir and tenofovir in hsCRP levels or 
levels of LDL or HDL cholesterol. Few participants in either group had levels of IL-6 or D-
dimer that were above the level of assay detection (0.70 pg/ml for IL-6 and 150 units for D-
dimer). IL-6 levels above the limits of assay detection were recorded in 11.3% (5/44) of the 
abacavir group and 8.5% (6/70) in the tenofovir group. For D-dimer, 7.0% (9/69) in the 
abacavir group had detectable levels as did 13.0% in the tenofovir group. The proportion 
with detectable IL-6 or D-dimer levels did not significantly differ in the abacavir and 
tenofovir groups. Triglycerides were significantly higher among those taking abacavir 
compared to those taking tenofovir (P=0.037; Table 2).
Wohl et al. Page 5













Among those in the zidovudine group, 16.7% (5/30) had an IL-6 value above the limits of 
assay detection and 27% (8/30) had quantifiable D-dimer levels. Triglycerides, but no other 
laboratory parameter, were significantly different among those treated with zidovudine 
compared to those treated with either abacavir or tenofovir (Table 2). There was a trend 
toward a lower proportion with detectable D-dimer in the abacavir group compared with the 
zidovudine group.
Discussion
Using a study design intended to minimize channelling bias that could lead to increased 
prescriptions for abacavir among individuals at greater risk of CVD, we found no significant 
difference in FMD among HIV-infected patients with controlled HIV infection receiving 
abacavir versus tenofovir, after adjustment for major confounders including brachial artery 
diameter, age and antiretroviral therapy duration, as well as CD4+ T-cell count, use of 
protease inhibitors, and use of statins. Notably, the abacavir and tenofovir groups were well-
balanced with the exception of a 5 month longer mean duration in HIV therapy and a higher 
proportion receiving protease inhibitor therapy in the abacavir group. Furthermore, 
measurements of hsCRP, IL-6 and D-dimer – markers of inflammation and coagulation – 
were not significantly different between the abacavir and tenofovir groups. Collectively, 
these results suggest that abacavir is no more associated with an inflammation-mediated 
impairment in endothelial function than is tenofovir.
Our FMD findings stand in contrast to a previous report, which described an independent 
association of abacavir use with impaired endothelial function in a cross-sectional study of 
antiretroviral-treated patients with suppressed HIV replication [9]. However, that study was 
from a single centre, was relatively small (n=61; 30 receiving abacavir), and participants 
were not randomly assigned to treatment with abacavir, leading to potentially important 
imbalances in the characteristics of those receiving and not receiving abacavir.
Additionally, markers of inflammation in our study were not significantly different among 
those treated with abacavir and tenofovir. By contrast, in A5224s, a recent metabolic 
substudy of the A5202 trial, participants receiving abacavir/lamivudine along with 
atazanavir/ritonavir or efavirenz experienced a significant increase in hsCRP levels over 96 
weeks, while among those receiving tenofovir/emtricitabine hsCRP levels changed little 
from baseline [10]. Interestingly, efavirenz was associated in this study with a sharp increase 
in hsCRP at week 24 but at 96 weeks was not significantly different than baseline. Although 
the majority of participants treated with abacavir and tenofovir in our study were originally 
enrolled in A5202, differences in the study designs, treatment duration, companion 
medications, and comorbid conditions may account for these discordant findings. It is 
notable that IL-6 levels in A5224s declined over time in both those treated with abacavir/
lamivudine- and tenofovir/emtricitiabine-containing regimens, although there was a lag in 
the timing of this decrease for abacavir/lamivudine relative to tenofovir/emtricitiabine. 
Furthermore, in the HEAT Trial, in which treatment-naive HIV-infected participants were 
randomized to abacavir/lamivudine or tenofovir/emtricitiabine plus lopinavir/ritonavir, 
hsCRP and IL-6, as well as sVCAM-1 (a marker of endothelial dysfunction) declined during 
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study follow-up similarly in both study arms [23]. However, those patients were viraemic at 
the onset of antiretroviral treatment.
As has been observed in previous studies, triglyceride levels were higher among participants 
receiving abacavir versus tenofovir [24,25]; however, it should be noted that a greater 
proportion of participants in the abacavir group were also receiving a protease inhibitor. 
These differences in triglycerides are modest and are unlikely to be responsible for an 
increased CVD risk with abacavir. Triglycerides were not significantly correlated with 
FMD.
In this study we also examined endothelial function, inflammation and coagulation in a 
small cohort of patients treated with zidovudine. As expected, these patients differed 
markedly from those in the abacavir and tenofovir groups in that they were older, had been 
on HIV therapy much longer, had higher CD4+ T-cell counts, and greater statin use than the 
other two groups. Furthermore, they were not assigned HIV therapy in a clinical trial. 
Therefore, given the differences between the zidovudine and the abacavir and tenofovir 
groups, any comparisons should be interpreted with a high level of caution. However, the 
zidovudine-treated patients provide some insights regarding the effect of long-term 
zidovudine-containing antiretroviral therapy on the parameters of interest. Endothelial 
function was observed to be better in the cohort of individuals receiving zidovudine 
compared with younger patients receiving abacavir or tenofovir for shorter durations; 
however, despite their lower FMD results, the zidovudine group tended to have higher 
hsCRP and D-dimer levels than the abacavir- and tenofovir-treated participants.
There are limitations to our study. Foremost, this was an observational cross-sectional study, 
and changes in the study outcomes over time could not be assessed. Furthermore, although 
major potentially confounding variables including age, antiretroviral therapy duration, statin 
therapy and CD4+ T-cell count were included in the modelling of our results, unmeasured 
factors that could have influenced the outcomes may have been missed. However, initial 
therapy with either abacavir or tenofovir was assigned in a randomized clinical trial, which 
would minimize imbalances between these groups. While this is the largest study to date to 
evaluate endothelial function among abacavir-treated patients, enrolment to the abacavir 
group did not reach the sample size goal and, therefore, modest FMD differences between 
abacavir and tenofovir may have been unrecognized. The International Brachial Artery Task 
Force [17] has stated that ‘typically, significant improvement in FMD can be seen with … 
40 to 60 patients in a parallel-group design study. In studies of this size, the minimal 
statistically significant improvement that can be detected with intervention is an absolute 
change in FMD of 1.5% to 2%.’ The American Society of Echocardiography [22] stated that 
‘in experienced laboratories with excellent reproducibility, a 2% to 3% improvement in 
FMD can be detected in … parallel-group trials with about 25 to 45 subjects per treatment 
arm.’ Our power analysis and recruitment targets are consistent with these 
recommendations. The study was conducted at multiple research centres, potentially adding 
variability to FMD assessments. However, a number of multicentre FMD studies have been 
successfully conducted, including among HIV-infected patients [26–29]. To minimize 
variability in FMD, ultrasonographers across centres were trained and certified by a central 
reading centre with rigorous quality assurance procedures in place. As mentioned above, the 
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zidovudine group was small and was included in the study in order to examine markers of 
endothelial function, inflammation and coagulation in patients receiving long-term therapy 
with this nucleoside analogue. Comparisons between this and the other groups was 
exploratory and should be interpreted with caution given differences between groups.
In summary, in this cross-sectional study, we found that individuals who were initially 
assigned randomly to abacavir or tenfovir in clinical trials did not differ significantly on 
measures of FMD, or markers of inflammation and coagulation. Whether abacavir 
contributes to risk of CVD events remains unclear, however, and our results suggest that 
impairment of endothelial function, heightened inflammation, and altered coagulation are, at 
most, of small magnitude and not likely to be mechanisms by which the drug could 
significantly increase CVD risk above that seen with tenofovir.
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